Claims for Commercial Purposes

• A 2020 study found:
• The Solumba technique has a recanalization rate of 86%.
• The Solumba technique requires fewer attempts to complete the MT procedure compared to ADAPT and SR.
• A 2018 study found:
• Patients treated with the combined technique were found to have better clinical outcomes and were less likely to die than patients undergoing SR.
• A 2016 study found:
• The Solumbra technique achieved recanalization of 88% at an average of 1.9 passes.
• The Solumbra technique has an average procedure time of 52.7 minutes.
• The Solumbra technique achieved a good functional outcome in 44% of cases.
• A 2018 study found:
• "The recanalizaton rate on first pass when using the Solumbra technique is 55.7% compared to 35.8% with SR and 34.4% with AD.
• The recanalizaton rate on first pass when using the Solumbra technique is 55.7% compared to 41.6% with SR and balloon catheter."
• A 2015 study found:
• The Solumbra technique has a lower rate of internal carotid thrombi (20%) when compared to the ADAPT technique (42.2%)..
• A 2018 study found:
• Using the Solitaire results in a QALY of 1.86 compared to 1.52 for the Trevo, 1.79 for the Penumbra, and 1.35 for the Solumbra.
• Using the Solitaire results in a net monetary benefit of $101,824, compared to $83,546 for the Trevo, $101,923 for the Penumbra, and $69,440 for the Solumbra.
• A 2017 study found:
• When treated using MEDtronic's Solitaire, patients at 12 months had improved functional dependence by 44% compared to 30% among those receiving medical therapy alone.
• When treated using MEDtronic's Solitaire, patients at 12 months had a health-related quality of life score of 0.46 compared to 0.33 among those receiving medical therapy alone.
• A 2015 study found:
• When treated using MEDtronic's Solitaire, patients had a functional dependence rate of 60% at 90 days compared to 35% among those receiving IV-tPA alone.
• When treated using MEDtronic's Solitaire, patients had a 90-day mortality rate of 9% compared to 12% among those receiving IV-tPA alone.
• When treated using MEDtronic's Solitaire, 0% of patients had a symptomatic intracranial hemorrhage compared to 3% of patients who received IV-tPA alone.
• A 2017 found:
• Treatment with Medtronic's Solitaire creates lifetime savings of $23,203 per patient when compared to treatment with IV-tPA alone.
• Treatment with MEDtronic's Solitaire resulted in increased QALY's of 0.131 compared to 0.105 among IV-tPA alone patients at 90 days.
• Treatment with MEDtronic's Solitaire resulted in increased QALY's of 6.79 compared to 5.05 among IV-tPA alone patients over a lifetime.